JP2018520205A5 - - Google Patents

Download PDF

Info

Publication number
JP2018520205A5
JP2018520205A5 JP2018511323A JP2018511323A JP2018520205A5 JP 2018520205 A5 JP2018520205 A5 JP 2018520205A5 JP 2018511323 A JP2018511323 A JP 2018511323A JP 2018511323 A JP2018511323 A JP 2018511323A JP 2018520205 A5 JP2018520205 A5 JP 2018520205A5
Authority
JP
Japan
Prior art keywords
formula
compound represented
crystalline form
mesylate salt
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018520205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/085360 external-priority patent/WO2016184436A1/zh
Publication of JP2018520205A publication Critical patent/JP2018520205A/ja
Publication of JP2018520205A5 publication Critical patent/JP2018520205A5/ja
Pending legal-status Critical Current

Links

JP2018511323A 2015-05-21 2016-06-08 レンバチニブメシル酸塩の新規結晶形及びその製造方法 Pending JP2018520205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510263300.3 2015-05-21
CN201510263300 2015-05-21
PCT/CN2016/085360 WO2016184436A1 (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Publications (2)

Publication Number Publication Date
JP2018520205A JP2018520205A (ja) 2018-07-26
JP2018520205A5 true JP2018520205A5 (OSRAM) 2018-09-06

Family

ID=57319484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511323A Pending JP2018520205A (ja) 2015-05-21 2016-06-08 レンバチニブメシル酸塩の新規結晶形及びその製造方法

Country Status (7)

Country Link
US (1) US10246418B2 (OSRAM)
EP (1) EP3287444A4 (OSRAM)
JP (1) JP2018520205A (OSRAM)
CN (2) CN107848979A (OSRAM)
IL (1) IL255738A (OSRAM)
MX (1) MX2017014799A (OSRAM)
WO (1) WO2016184436A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202799B1 (en) 2014-09-30 2021-08-25 LG Chem, Ltd. Block copolymer
US10562855B2 (en) * 2016-06-08 2020-02-18 Crystal Pharmatech Co., Ltd. Crystalline form of lenvantinib mesylate and process of preparation thereof
US11084791B2 (en) 2016-12-29 2021-08-10 Dr. Reddy's Laboratories Limited Solid state forms of Lenvatinib Mesylate
WO2018196687A1 (zh) * 2017-04-25 2018-11-01 苏州科睿思制药有限公司 乐伐替尼甲磺酸盐的新晶型及其制备方法
WO2019111283A1 (en) * 2017-12-09 2019-06-13 Msn Laboratories Private Limited, R&D Center Novel polymorphs of 4-[3-chloro-4-(n'-cyclopropyl ureido)phenoxy]-7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
US11634388B2 (en) 2018-06-01 2023-04-25 Chengdu Easton Biopharmaceuticals Co., Ltd. Crystal form of lenvatinib mesylate and preparation method therefor
CN110818634B (zh) * 2018-08-13 2021-11-30 上海新礼泰药业有限公司 甲磺酸乐伐替尼的精制方法
EP3620453A1 (en) 2018-09-07 2020-03-11 Indena S.p.A. New crystal form of lenvatinib
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN111689897B (zh) * 2019-03-13 2024-02-06 齐鲁制药有限公司 一种高纯度甲磺酸乐伐替尼晶型c的制备方法
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法
CN110229103A (zh) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 一种乐伐替尼甲磺酸盐晶型b的制备方法
CN112174886A (zh) * 2019-07-02 2021-01-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼晶型x的制备方法
MX2022000311A (es) * 2019-07-08 2022-04-20 Rezolute Inc Formas cristalinas de inhibidores de calicreina plasmatica.
CN110563644A (zh) * 2019-10-30 2019-12-13 北京赛思源生物医药技术有限公司 一种仑伐替尼甲磺酸盐的新晶型
US11059787B2 (en) 2019-11-12 2021-07-13 Shenzhen Bolan Pharmaceutical Co., Ltd Crystalline form of lenvatinib mesylate and methods thereof
CN113135853A (zh) * 2020-01-19 2021-07-20 重庆医药工业研究院有限责任公司 一种氟伐替尼或甲磺酸盐的晶型及其制备方法
KR102581450B1 (ko) * 2020-04-24 2023-09-21 청두 이스턴 바이오파마슈티컬 컴퍼니 리미티드 렌바티닙 메실레이트의 결정형 xi 및 이의 제조방법
CN112939859B (zh) * 2021-02-03 2022-03-11 南京方生和医药科技有限公司 甲磺酸仑伐替尼m晶型的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CN101337931B (zh) 2003-12-25 2010-09-29 卫材R&D管理有限公司 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CN101233111A (zh) * 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
BR112012003592B8 (pt) * 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina

Similar Documents

Publication Publication Date Title
JP2018520205A5 (OSRAM)
RU2017142958A (ru) Кристаллы азабициклического соединения
JP2015078199A5 (OSRAM)
JP2014524442A5 (OSRAM)
JP2013543867A5 (OSRAM)
RU2015100280A (ru) Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи
JP2016128501A5 (OSRAM)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
RU2017115925A (ru) Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
RU2018145948A (ru) Кристалл пирролопиримидина для получения jak-ингибитора
HRP20210194T1 (hr) Nove soli i njihove farmaceutske kompozicije za liječenje inflamatornih poremećaja
JP2015010091A5 (OSRAM)
JP2015522037A5 (OSRAM)
JP2014530818A5 (OSRAM)
CN110088088A (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
TN2015000367A1 (fr) Nouveau sel de l'abexinostat, forme cristalline associee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HRP20241280T1 (hr) Kruti oblici rukapariba i soli rukapariba
JP2019520321A5 (OSRAM)
JP2015516425A5 (OSRAM)
CN109563059A (zh) 奥扎莫德的晶型及其制备方法
JP2013523623A5 (OSRAM)
RU2017134709A (ru) П-толуолсульфонат для ингибитора мек-киназы и его кристаллическая форма, и способ его получения
WO2016103262A3 (en) Crystal forms of apomorphine and uses thereof
CN114787152A (zh) 一种bms-986165晶型及其制备方法和用途
JP2017535510A5 (OSRAM)